{"_id": "64ffe82b748b29c10bbbeb05", "and": 8, "prostate cancer histology": 1, "prostate cancer progression on androgen deprivation therapy": 1, "metastatic disease": 1, "bone lesions": 1, "soft tissue disease": 1, "abiraterone acetate exposure": 1, "androgen deprivation": 1, "bone resorptive therapy": 1, "refrain from donating sperm": 1, "be abstinent": 1, "must agree to use male condom": 1, "biopsy sample": 1, "soft tissue biopsy": 1, "bone biopsy": 1, "ECOG performance status": 2, "additional malignancy": 1, "autoimmune disease": 1, "immunodeficiency": 1, "major surgery": 1, "gastrointestinal disorder": 1, "active infection": 1, "pneumonitis/interstitial lung disease": 1, "HIV infection": 1, "CNS metastases": 1, "hypersensitivity": 1, "seizure history": 1, "loss of consciousness history": 1, "hypotension": 1, "bradycardia": 1, "ketoconazole treatment": 1, "prior anti-PD-1/PD-L1/PD-L2 therapy": 1, "prior radium or radiopharmaceutical treatment": 1, "prior docetaxel or chemotherapy treatment": 1, "prior anti-cancer monoclonal antibody therapy": 1, "herbal product use": 1, "live vaccine use": 1, "participation in investigational study": 1, "'superscan' bone scan": 1, "expecting to conceive or father children": 1, "allogenic tissue/solid organ transplant": 1, "diagnosis": 4, "histological diagnosis": 1, "days since surgical resection prior to treatment on the trial": 1, "Karnofsky performance status": 1, "adequate organ function laboratory values": 1, "resting baseline O2 saturation by pulse oximetry": 1, "able to provide written informed consent/assent for the trial": 1, "life expectancy": 1, "willingness to discontinue medications known to be associated with risk of Torsades de Pointes": 1, "such as": 1, "single lesion < 4 cm in longest diameter (diameter of enhancing lesion)": 1, "prior anti-cancer therapy for glioblastoma": 1, "females of childbearing potential (FOCBP) negative pregnancy test": 1, "urine test is positive": 1, "cannot be confirmed as negative": 1, "females and males of childbearing potential must be willing to use an adequate method of contraception per protocol for the course of the study through 120 days after the last dose of study medication": 1, "abstinence is acceptable if this is the usual lifestyle and preferred contraception for participant": 1, "use of Optune device is allowed": 1, "prior treatment of glioblastoma (GBM) with radiation and temozolomide": 1, "evidence of leptomeningeal disease": 1, "prior treatment with Gliadel": 1, "unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain": 1, "currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment": 1, "diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment": 1, "physiologic doses of steroid therapy (\u2264 2 mg/day dexamethasone equivalents) by the time of first dose of treatment are allowed": 1, "known history of active Bacillus Tuberculosis (TB)": 1, "hypersensitivity to pembrolizumab or any of its excipients": 1, "prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier": 1, "prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent": 1, "known additional malignancy that is progressing or requires active treatment": 1, "basal cell carcinoma of the skin that has undergone potentially curative therapy": 1, "squamous cell carcinoma of the skin that has undergone potentially curative therapy": 1, "in situ cervical cancer": 1, "active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)": 1, "replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.)": 1, "patients with vitiligo or resolved childhood asthma/atopy": 1, "patients that require intermittent use of bronchodilators or local steroid injections": 1, "patients with hypothyroidism stable on hormone replacement": 1, "patients with Sjorgen's syndrome": 1, "known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy": 1, "active serious infection requiring systemic therapy": 1, "major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study": 1, "history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate": 1, "known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial": 1, "pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment": 1, "prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent": 1, "known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)": 1, "known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)": 1, "received a live vaccine within 30 days of planned start of study therapy": 1, "cancer type": 4, "HER2 amplification/overexpression": 1, "uterine serous carcinoma": 1, "HER2-mutated gastric adenocarcinoma": 1, "HER2-mutated gastroesophageal junction adenocarcinoma": 1, "HER2-directed therapy": 1, "hypersensitivity to drug formulation": 1, "exposure to cumulative dose of anthracyclines": 1, "recent treatment or participation in another clinical trial": 1, "primary site": 1, "days since surgery": 1, "biopsy under general anesthesia": 1, "extracapsular nodal extension": 1, "invasive cancer at resection margin": 1, "pathologic stage": 1, "distant metastases": 1, "last examination by radiation oncologist or medical oncologist": 1, "last examination by ENT or head & neck surgeon": 1, "last neck CT scan": 1, "last chest CT scan": 1, "Zubrod performance status": 1, "age": 4, "absolute granulocyte count": 1, "platelets": 2, "hemoglobin": 1, "total bilirubin": 2, "AST": 1, "serum creatinine": 1, "creatinine clearance": 2, "negative pregnancy test": 1, "sodium": 1, "magnesium": 1, "magnesium supplementation": 1, "feeding tubes": 1, "effective birth control": 1, "informed consent": 1, "prior invasive malignancy": 1, "simultaneous primaries or bilateral tumors": 1, "prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy": 1, "prior radiotherapy to the region of the study cancer": 1, "unstable angina and/or congestive heart failure": 1, "transmural myocardial infarction": 1, "acute bacterial or fungal infection requiring intravenous antibiotics": 1, "chronic obstructive pulmonary disease exacerbation or other respiratory illness": 1, "idiopathic pulmonary fibrosis or other severe interstitial lung disease": 1, "hepatic insufficiency resulting in clinical jaundice and/or coagulation defects": 1, "acquired immune deficiency syndrome (AIDS)": 1, "grade 3-4 electrolyte abnormalities": 1, "pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception": 1, "prior allergic reaction to cetuximab": 1, "metastasized to the brain": 1, "primary origin": 1, "uveal primary": 1, "BRAF-V600 mutant melanoma": 1, "MRI of the brain within 28 days prior to registration": 1, "central nervous system metastases with at least one measurable brain metastasis >= 0.5 cm in size": 1, "recommended MRI acquisition protocol": 1, "CT of the head cannot substitute for brain MRI": 1, "CNS disease documented on both Brain Metastases Baseline Tumor Assessment Form and Baseline Tumor Assessment Form": 1, "measurable or non-measurable extracranial disease": 1, "measurable disease assessed within 28 days prior to randomization": 1, "non-measurable disease assessed within 42 days prior to randomization": 1, "disease documented on Baseline Tumor Assessment Form": 1, "leptomeningeal disease": 1, "corticosteroids for brain metastases at a dose of up to 8 mg of dexamethasone per day for at least 7 days prior to randomization": 1, "Zubrod performance status =< 2": 1, "complete history and physical examination within 28 days prior to randomization": 1, "able to swallow and retain pills": 1, "hemoglobin >= 8.0 g/dL within 28 days prior to randomization": 1, "absolute neutrophil count >= 1,500/mcL within 28 days prior to randomization": 1, "platelets >= 75,000/mcL within 28 days prior to randomization": 1, "total bilirubin =< 1.5 institutional upper limit of normal (ULN) within 28 days prior to randomization": 1, "AST and ALT =< 2.5 x institutional ULN (in participants with liver metastases =< 5 x ULN) within 28 days prior to randomization": 1, "creatinine =< 2.0 institutional ULN within 28 days prior to randomization": 1, "known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents": 1, "clinical risk assessment of cardiac function using the New York Heart Association Functional Classification": 1, "NYHA class =< 2B": 1, "prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen": 1, "eligible for this trial": 1, "known human immunodeficiency virus (HIV)-infection": 1, "on effective anti-retroviral therapy and undetectable viral load at their most recent viral load test and within 90 days prior to randomization": 1, "known history of hepatitis C virus (HCV) infection": 1, "treated and cured": 1, "undetectable HCV viral load prior to randomization": 1, "image banking participation": 1, "offered opportunity to participate in specimen and blood collections": 1, "informed of the investigational nature of this study and signed informed consent": 1, "institutional review board approval within 365 days": 1, "prior systemic therapy for metastatic disease": 1, "prior radiation therapy within 7 days prior to randomization": 1, "additional form of systemic anti-tumor therapy for melanoma while on protocol treatment": 1, "use of hormonal contraceptives": 1, "serious active infection requiring systemic therapy at time of randomization": 1, "active autoimmune disease requiring treatment in the past 6 months with biologic disease modifying agents": 1, "grade 3 or 4 immune-related adverse events on ipilimumab or nivolumab requiring more than 12 weeks of immune suppression with corticosteroids": 1, "adverse events related to encorafenib and/or binimetinib requiring discontinuation of one or both drugs": 1, "pregnant or nursing": 1, "known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, clinical risk assessment of cardiac function using the New York Heart Association Functional Classification, NYHA class =< 2B": 1, "known human immunodeficiency virus (HIV)-infection on effective anti-retroviral therapy and undetectable viral load at their most recent viral load test and within 90 days prior to randomization": 1, "known history of hepatitis C virus (HCV) infection treated and cured, undetectable HCV viral load prior to randomization": 1, "consultation with the Medical Monitor": 2, "additional line of therapy with appropriate targeted therapy for patients with actionable mutations (other than EGFR, ALK, or ROS genomic alterations)": 2, "documented radiographic disease progression on or after the first-line therapy": 2, "concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab": 2, "no more than 1 prior line if ICI and platinum-based chemotherapy were administered concurrently": 2, "no more than 2 prior lines for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines": 2, "LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination": 2, "meet all eligibility criteria except documented disease progression": 2, "intend to receive TIL therapy after disease progression": 2, "prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy": 1, "resectable lesion for TIL production": 2, "remaining measurable lesion": 1, "adequate organ function": 2, "LVEF > 45%, NYHA Class 1": 2, "adequate pulmonary function": 2, "ECOG performance status of 0 or 1": 2, "patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy": 1, "EGFR driver mutation": 2, "ALK driver mutation": 2, "ROS driver mutation": 2, "symptomatic, untreated brain metastases": 2, "allogeneic organ transplant or prior cell therapy within the past 20 years": 2, "any form of primary immunodeficiency": 2, "systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent": 1, "live or attenuated vaccination within 28 days prior to the start of treatment": 1, "another primary malignancy within the previous 3 years": 1, "participation in another interventional clinical study within 21 days": 2, "surgery": 1, "margins": 1, "ENE": 1, "PD-L1 CPS": 1, "prior radiation": 1, "completed prior radiation": 1, "evidence of distant disease": 1, "anti-PD-1/PD-L1 therapy": 1, "able to consent": 1, "IDMC": 1, "LAR or caregiver available": 1, "pregnant": 1, "breast-feeding": 1, "blood test or urine study": 1, "urine or serum pregnancy test": 1, "serum pregnancy test": 1, "patient of childbearing potential": 1, "achieved menarche": 1, "hysterectomy or bilateral oophorectomy": 1, "naturally postmenopausal": 1, "expect to conceive or father children": 1, "ANC": 1, "AST/ALT": 1, "current active infection": 1, "non-infectious pneumonitis": 1, "history of transplant": 1, "immunosuppressive medication": 1, "steroids": 1, "systemic corticosteroids": 1, "steroids as premedication": 1, "cardiac function": 1, "live vaccine": 1, "severe hypersensitivity": 1, "active autoimmune disease": 1, "replacement therapy": 1, "psychiatric or substance abuse disorder": 1, "HIV-infected patients": 1, "hepatitis B": 1, "hepatitis C virus": 1, "prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy": 1, "count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy": 1, "remaining measurable lesion, as defined by RECIST v1.1": 1, "patients of childbearing potential or those with partners of childbearing potential": 1, "willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy": 1, "on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent": 1, "received a live or attenuated vaccination within 28 days prior to the start of treatment": 1, "had another primary malignancy within the previous 3 years": 1, "cancer stage": 1, "resectable": 1, "pathologically confirmed": 1, "nodal recurrence after surgery for early stage NSCLC": 1, "ECOG status": 1, "body weight": 1, "unintentional weight loss": 1, "baseline electrocardiography (ECG)": 1, "measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1": 1, "Absolute neutrophil count (ANC)": 1, "White blood cells (WBC) counts": 1, "Platelet count": 1, "Hemoglobin": 1, "Total bilirubin": 1, "Aspartate aminotransferase (AST) and alanine transaminase (ALT)": 1, "Serum creatinine": 1, "pulmonary function tests (PFTs) with both forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO)": 1, "lung volume (V)20": 1, "nodal recurrence after surgery for early-stage NSCLC": 1, "No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol": 1, "Prior curative-intent surgery was at least 90 days prior to the nodal recurrence": 1, "No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields": 1, "human immunodeficiency virus (HIV) positive": 1, "stable on their anti-retroviral regimen": 1, "healthy from an HIV perspective": 1, "CD4 count": 1, "not receiving prophylactic therapy for an opportunistic infection": 1, "prior or concurrent malignancy": 1, "chemotherapy or radiotherapy within 4 weeks": 1, "pregnant or breast-feeding": 1, "negative blood test or urine study": 1, "expected to conceive or father children": 1, "active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes": 1, "history of active hepatitis B or hepatitis C infection": 1}